Clinical trial
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
NCT05649748 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
- Lead sponsor
- Insmed Incorporated
- Phase
- Phase 2/3
- Overall status
- Active, not recruiting
- Start date
- March 7, 2023
- Completion date
- December 31, 2026
- Enrollment
- 91 (actual)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.